iCell Cardiomyocytes

Scientific Founders

Dr. James ThomsonJames A. Thomson, VMD, Ph.D.

Dr. Thomson is one of our founders and has served as our Chief Scientific Officer and as a member of our board of directors since 2007. He received a VMD and a Ph.D. from the University of Pennsylvania. He is a member of the National Academy of Sciences, and has served as the Director of Regenerative Biology at the Morgridge Institute for Research since 2008 and as the John D. MacArthur Professor of Anatomy at the University of Wisconsin-Madison since 2003. Dr. Thomson’s derivation of human ES cells was featured as Science Magazine’s “Scientific Breakthrough of the year” in 1999, and work from Dr. Thomson’s laboratory has been cited in TIME Magazine's “Top 10 Discoveries of the Year” on three separate occasions, including the isolation of human ES cells (1998, #1), the isolation of human iPS cells (2007, #1) and the collaborative mapping of the human epigenome (2009, #2). He was featured on the cover of TIME Magazine’s “America’s Best in Science and Medicine” in 2001, and in 2007 was named one of TIME Magazine’s “100 Most Influential People in the World.” Dr. Thomson has published over 150 scientific, peer-reviewed papers and has been an inventor on 30 issued patents.

Dr. Craig JanuaryCraig T. January, MD, Ph.D. Founder

For the past 20 years, Dr. January has been a leading international authority in the field of cardiac arrhythmias, including long QT syndrome. Dr. January's work has had significant industry and regulatory impact, and he has consulted to multiple large and small pharmaceutical companies. He was one of the first scientists to stably express hERG potassium channels in a human cell system (HEK293 cells), and these cells are now distributed world-wide for use in drug toxicity screening. His work helped to identify drugs that caused high-affinity hERG potassium channel block, and his studies helped lead to the withdrawal of several QT interval prolonging drugs from the marketplace. Screening of new drugs and lead compounds for this hERG liability is now a broadly established technology required by regulatory agencies worldwide. Dr. January's technology is the basis for CDI's hERG screening program. Dr. January holds an MD and PhD in Physiology and Biophysics from the University of Iowa. He is a practicing cardiologist and is a Professor in the Department of Medicine in the Division of Cardiovascular Medicine at the University of Wisconsin-Madison, School of Medicine and Public Health.

Dr. Timothy KampTimothy J. Kamp, MD, Ph.D.

Dr. Kamp is a practicing cardiologist and Professor of Medicine and Physiology at the University of Wisconsin-Madison, School of Medicine and Public Health. He also serves as Co-Director of the UW Stem Cell and Regenerative Medicine Center. Dr. Kamp's research program explores the basic mechanisms controlling the electrical activity of the heart and cardioregenerative medicine. CDI's cardiomyocyte product lines are based upon work begun in Dr. Kamp's laboratory at the UW. Dr. Kamp, in collaboration with Dr. Thomson, provided one of the first descriptions and characterizations of cardiomyocytes derived from human embryonic stem cells. Dr. Kamp holds both an MD and PhD in pharmacology and physiological sciences from the University of Chicago. He trained in Internal Medicine and Cardiovascular Medicine at Johns Hopkins University.

Igor Slukvin, MD, Ph.D.

Dr. Igor Slukvin is Associate Professor in the Department of Pathology and Laboratory Medicine at the University of Wisconsin School of Medicine and Public Health. Dr. Slukvin’s research focus is the development of systems to culture hematopoietic precursors and red blood cells from human pluripotent cells. Dr. Slukvin holds an MD and PhD from the Kiev Medical Institute in the Ukraine. Dr. Slukvin completed his medical residency at the University of Wisconsin and has published over 68 scientific, peer-reviewed papers.